India, Oct. 7 -- AstraZeneca Pharma announced on Tuesday that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to market and distribute its cancer drug Trastuzumab Deruxtecan in India for an additional indication.
The drug is now approved for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumours who have received prior systemic therapy and have no satisfactory alternative treatment options, the company stated.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....